BMS and Century Therapeutics Will Combine Cell Therapy Forces Against Cancer

Century Therapeutics and Bristol Myers Squibb (BMS) are collaborating on four programs for hematologic malignancies and tumors.

BMS, which has a presence in Seattle, will be responsible for clinical development and commercialization of development candidates as a part of the deal while Century will generate development candidates and preclinical development activities for each program.

“We are pleased to partner with Bristol Myers Squibb, a global leader in oncology and hematology, to further expand our pipeline of iPSC-derived cell therapy products for challenging hematological and solid tumor malignancies,” said Osvaldo Flores, Ph.D., CEO of Century Therapeutics.

READ THE STORY at BioSpace »